Avalyn完成AP01(吸入性吡非尼酮)针对进展性肺纤维化患者的2b期Mist试验目标入组

美股速递
Jun 17

Avalyn Pharma宣布,其针对进展性肺纤维化患者研发的药物AP01(吸入性吡非尼酮)的2b期Mist临床试验,现已完成目标患者入组工作。这一关键里程碑标志着该试验已进入新的数据收集与分析阶段,为评估该吸入式疗法的有效性与安全性奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10